Update shared on 24 Oct 2025
Fair value Increased 1.17%Narrative Update on Ipsen: Analyst Price Target Adjustment
Analysts have slightly increased their price target for Ipsen from $128.43 to $129.93. This adjustment is attributed to minor shifts in revenue growth forecasts and updated profit margin estimates.
What's in the News
- Ipsen upgraded its 2025 earnings guidance, forecasting total sales growth of around 10.0% at constant exchange rates and a core operating margin of around 35.0% of total sales (Key Developments).
- Japan's Ministry of Health, Labour and Welfare granted regulatory approval for Bylvay (odevixibat) to treat pruritus associated with progressive familial intrahepatic cholestasis (PFIC), following positive results from a Phase III study in Japan (Key Developments).
- Health Canada approved Bylvay (odevixibat) for treatment of cholestatic pruritus in patients 12 months and older with Alagille Syndrome, expanding its use beyond previous indications (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has risen slightly from $128.43 to $129.93.
- Discount Rate remains virtually unchanged at 5.98%.
- Revenue Growth Forecast has fallen from 4.71% to 3.97%.
- Net Profit Margin estimate has decreased marginally from 18.61% to 18.50%.
- Future P/E ratio has increased from 15.60x to 16.23x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.